Key Takeaways:
- The global animal parasiticides market is projected to grow at a 6.2% CAGR from 2026 to 2031.
- Market size is expected to increase from $12.98 billion in 2026 to $17.50 billion by 2031.
- Ectoparasiticides represent the largest and fastest-growing product segment.
- Companion animals accounted for 57.8% of market share in 2025.
- Veterinary hospitals and clinics held 61.1% of end-user share in 2025.
- Latin America is forecast to register the highest regional CAGR at 7.7%.
The global animal parasiticides market is positioned for sustained expansion through 2031, supported by rising pet ownership, increased preventive healthcare awareness, and continued innovation in parasite control technologies.
According to MarketsandMarkets™, the market is projected to grow from approximately $12.98 billion in 2026 to $17.50 billion by 2031. Growth is being driven by strong demand across companion and food-producing animal segments, alongside the adoption of advanced treatment solutions.
Technology Reshaping Parasite Management
Technological developments are playing a central role in market expansion. Innovations include long-acting formulations, precision parasite control strategies, and data-enabled treatment approaches that improve compliance and long-term outcomes.
Artificial intelligence and advanced analytics are increasingly used in parasite surveillance and resistance management programs. At the same time, improvements in formulation science and delivery systems are enhancing product efficacy and shelf life.
Rapid diagnostic tools and wearable animal health technologies are also supporting earlier detection of parasite infestations and enabling real-world monitoring of treatment effectiveness.
A notable example of this shift toward extended-duration therapies is the July 2025 FDA approval of Bravecto Quantum (fluralaner extended-release injectable suspension), a 12-month flea and tick injectable for dogs. The approval reflects broader industry momentum toward precision-driven, long-acting solutions that reduce dosing frequency while maintaining efficacy.
Segment Insights
By Product Type: Ectoparasiticides accounted for the largest market share in 2025 and are expected to register the highest CAGR of 7.0% during the forecast period. The segment’s dominance is driven by the high prevalence of external parasites such as fleas, ticks, and mites, along with increased adoption of year-round preventive care and long-acting oral and topical products.
By Animal Type: Companion animals represented 57.8% of the market in 2025, reflecting continued growth in pet healthcare spending and strong consumer focus on preventive treatment protocols.
By End User: Veterinary hospitals and clinics held 61.1% of market share in 2025, maintaining their role as the primary channel for prescription and advanced parasiticide administration. Home care settings are projected to experience the fastest growth during the forecast period, supported by stronger veterinarian-client relationships and improved access to professional diagnostics and preventive programs.
Regional Outlook
North America accounted for the largest share of the global market in 2025. Market leadership is attributed to high pet ownership rates, advanced veterinary infrastructure, strong preventive care practices, and early adoption of long-acting parasiticide products.
Latin America is expected to record the highest CAGR of 7.7% from 2026 to 2031, driven by expanding animal health investments and increased awareness of parasite management.
Competitive Landscape
Leading companies operating in the global animal parasiticides market include Zoetis Services LLC, Merck & Co., Inc., Elanco, Boehringer Ingelheim International GmbH, Virbac, Ceva, Vetoquinol, Dechra Pharmaceuticals PLC, Phibro Animal Health Corporation, and Norbrook.
Information sourced from the company’s press release.
